Big Pharma Split Corp Class A (PRM) — Cash Flow Quality Index
Big Pharma Split Corp Class A (PRM) has a Cash Flow Quality Index of -0.34x as of June 2024. Operating cash flow of CA$-422.10K is below net income of CA$1.24 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how efficiently does Big Pharma Split Corp Class A generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Big Pharma Split Corp Class A Cash Flow Quality Index (2018–2022)
Historical Cash Flow Quality Index for Big Pharma Split Corp Class A across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Big Pharma Split Corp Class A investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Big Pharma Split Corp Class A (2018–2022)
Year-by-year earnings quality comparison for Big Pharma Split Corp Class A. For live market cap and the full company financial profile, see Big Pharma Split Corp Class A (PRM) total market value.
| Year | Quality Index | Operating CF (CAD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 0.47x | CA$1.13 Million | CA$2.39 Million | ▲ +122.1% |
| 2021 | -2.14x | CA$-9.00 Million | CA$4.21 Million | ▼ -163.6% |
| 2019 | 3.36x | CA$8.68 Million | CA$2.58 Million | ▲ +457.3% |
| 2018 | 0.60x | CA$1.27 Million | CA$2.10 Million | — |